PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

Judith van Loon*, Aniek J. G. Even, Hugo J. W. L. Aerts, Michel Ollers, Frank Hoebers, Wouter van Elmpt, Ludwig Dubois, Anne-Marie C. Dingemans, Roy I. Lalisang, Pascal Kempers, Boudewijn Brans, Veronique Winnepenninckx, Ernst-Jan Speel, Eric Thunnissen, Kim M. Smits, Ronald Boellaard, Danielle J. Vugts, Dirk De Ruysscher, Philippe Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalRadiotherapy and Oncology
Volume122
Issue number2
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Zr-89-cetuximab
  • EGFR
  • Immuno-PET
  • Phase I trial
  • GROWTH-FACTOR RECEPTOR
  • MONOCLONAL-ANTIBODIES
  • PLUS CETUXIMAB
  • 1ST-LINE CHEMOTHERAPY
  • EGFR-INHIBITION
  • IMMUNO-PET
  • EXPRESSION
  • RADIOTHERAPY
  • CARCINOMA
  • SURVIVAL

Cite this